SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. The purpose of this study is to help answer the following questions: How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? Can SPD489 help patients with depression who are also taking an antidepressant? How much SPD489 should be given to patients with depression who are also taking an antidepressant? How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Official Title
-----------------
A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
* Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
* Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
* Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
* Drug: Antidepressant + Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Subject is able to provide written, personally signed and dated informed consent to participate in the study before completing any study-related procedures. Subject is between 18-65 years of age. Subject has a primary diagnosis of non-psychotic MDD. Subject has a MADRS total score 24 Subject is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol. Subject, who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test and agrees to comply with any applicable contraceptive requirements. Subject is able to swallow a capsule. Exclusion Criteria Subject whose current episode of MDD has not responded to an adequate treatment regimen. Subject who has a lifetime history of treatment resistant depression, defined as having not responded to adequate treatment with 2 or more treatment regimens. Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms. Subject has been hospitalized (within the last 12 months) for their current MDD episode. Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD). Subject has a first degree relative that has been diagnosed with bipolar I disorder. Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder. Subject is considered a suicide risk, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation. Subject has a concurrent chronic or acute illness or unstable medical condition. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medication. Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit. Subject has a known family history of sudden cardiac death or ventricular arrhythmia. Subject has glaucoma. Subject has any clinically significant ECG or clinical laboratory abnormalities at the Screening Visit. Subject has a history of moderate to severe hypertension. Current use of any other medication (including over-the-counter [OTC], herbal or homeopathic preparations) that has central nervous system effects. Subject has the potential to need to initiate or modify frequency of psychotherapy or to continue or initiate other treatments for depression, outside of those allowed in this protocol. Subject has had electroconvulsive therapy for the current depressive episode 3 months prior to the Lead-in Baseline Visit. The subject has a known or suspected intolerance or hypersensitivity to the investigational product. The subject has a known or suspected intolerance or hypersensitivity to any of the possible antidepressant treatments (escitalopram oxalate or venlafaxine HCL extended release. Subject has a positive urine drug result. Subject has a body mass index of <18.5 or >40. Subject is female and is pregnant or nursing. Subject has participated in another clinical study involving SPD489/NRP104 or has previously used commercial lisdexamfetamine dimesylate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antidepressant + SPD489 10 mg<br> | Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg<br>* Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks<br>* Other names: Vyvanse;|
| Experimental: Antidepressant + SPD489 30 mg<br> | Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg<br>* Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks<br>* Other names: Vyvanse;|
| Experimental: Antidepressant + SPD489 50 mg<br> | Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg<br>* Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks<br>* Other names: Vyvanse;|
| Experimental: Antidepressant + SPD489 70 mg<br> | Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg<br>* Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks<br>* Other names: Vyvanse;|
| Placebo Comparator: Antidepressant + Placebo<br> | Drug: Antidepressant + Placebo<br>* oral, once daily for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16. | Augmentation Baseline (Week 8) to Week 16 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 |  | From Augmentation Baseline (Week 8) to Week 16 | 
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 |  | From Augmentation Baseline (Week 8) to Week 16 | 
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 |  | From Augmentation Baseline (Week 8) to Week 16 |